1
Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma
Condition(s): Bladder Cancer Last Updated: August 2, 2012Terminated
1464 Clinical Trials for: RAD001, Page 1 of 74
Hide Studies Not Seeking New Volunteers
2
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
Condition(s): Non-Small Cell Lung Cancer Last Updated: July 2, 2012Terminated
3
Study of RAD001 (Everolimus) for Children With NF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
Condition(s): Glioma Last Updated: April 25, 2013Recruiting
4
Phase II Trial of RAD001 in Patients With Recurrent Low Grade Glioma
Condition(s): Low-grade Glioma; Astrocytoma; Oligodendroglioma; Mixed Oligoastrocytoma Last Updated: May 6, 2013Recruiting
5
Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors
Condition(s): Advanced Solid Tumors; Metastatic Breast Cancer; Metastatic Renal Cell Carcinoma Last Updated: April 15, 2013Recruiting
6
Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
Condition(s): Tuberous Sclerosis Complex Last Updated: August 8, 2012Recruiting
7
Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer
Condition(s): Non-small Cell Lung Cancer; Locally Advanced Disease Last Updated: April 3, 2012Recruiting
8
RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer
Condition(s): HEAD & NECK Cancer Last Updated: October 29, 2012Active, not recruiting
9
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Condition(s): Waldenstrom's Macroglobulinemia Last Updated: April 30, 2013Active, not recruiting
10
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
Condition(s): Advanced Cancer; Solid Tumor Last Updated: February 25, 2013Recruiting
11
Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium
Condition(s): Bladder Cancer; Metastatic Transitional Cell Carcinoma Last Updated: July 23, 2012Active, not recruiting
12
Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
Condition(s): Chronic Allograft Nephropathy Last Updated: January 18, 2013Recruiting
13
Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy
Condition(s): Diffuse Large B-cell Lymphoma Last Updated: January 17, 2013Recruiting
14
Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor
Condition(s): Neuroendocrine Tumors; Carcinoid Tumor Last Updated: August 3, 2010Active, not recruiting
15
Radiation Therapy (IMRT) + RAD001 (Everolimus) + Cisplatin for Patients With Head and Neck Cancer
Condition(s): Head and Neck Cancer Last Updated: February 28, 2013Active, not recruiting
16
RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib
Condition(s): Metastatic Renal Cell Carcinoma Last Updated: December 7, 2012Completed
17
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab in Adult Patients With Kidney Cancer
Condition(s): Carcinoma, Renal Cell; Adenocarcinoma, Renal Cell; Nephroid Carcinoma; Carcinoma, Hypernephroid Last Updated: May 10, 2013Completed
18
Study of RAD001 and Bevacizumab in Recurrent Ovarian, Peritoneal, and Fallopian Tube Cancer
Condition(s): Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer Last Updated: March 13, 2013Recruiting
19
Randomized Phase I/II of RAD001 in Advanced Hepatocellular Carcinoma (HCC)
Condition(s): Hepatocellular Carcinoma Last Updated: June 29, 2009Recruiting
20
Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity
Condition(s): Malignant Pleural Mesothelioma Last Updated: September 19, 2012Completed
